ENTEROLOGICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-08-22: Form 8-K/A; Period of report 2013-08-15; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2013-08-19: Form 8-K; Period of report 2013-08-15; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2012-03-23: Form 8-K/A; Period of report 2012-03-19; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2012-03-19: Form 8-K; Period of report 2012-03-19; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-08-22 | 8-K/A | 2013-08-15 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On August 13, 2013, the Public Company Accounting Oversight Board ("PCAOB") issued an order which, among other things, revoked the PCAOB registration of Lake & Associates, CPA’s, LLC (“Lake & Associates”), the Company's prior independent registered public accounting firm. | elgo_8ka.htm |
| 2013-08-19 | 8-K | 2013-08-15 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On August 15, 2013, Enterologics, Inc. (the “Company”) was informed that Lake & Associates, CPA’s (“Lake”) could no longer serve as principal independent accountants for the Company. | elgo_8k.htm |
| 2012-03-23 | 8-K/A | 2012-03-19 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On March 19, 2012, the Company changed its principal independent accountants. | elgo_8ka.htm |
| 2012-03-19 | 8-K | 2012-03-19 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On March 19, 2012, Enterologics, Inc. (the “Company”) changed its principal independent accountants. | elgo_8k.htm |
| 2012-03-16 | 8-K/A | 2011-09-16 | 9.01 Financial Statements and Exhibits | 9.01 (a) Financial statements of Businesses Acquired. | elgo_8ka.htm |
| 2012-01-31 | 8-K | 2012-01-11 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On January 11, 2012, Enterologics, Inc., a Nevada corporation (the “Company”), entered into an agreement with MBTA Management, LLC, a Pennsylvania limited liability company (“MBTA”), pursuant to which MBTA will lend the Company an aggregate of $100,000 as follows - $50,000 on or before January 16, 2012, $25,000 may be requested by the Company at any time after February 1, 2012 and an additional $25,000 which may be requested after February 15, 2012. 2.03 The disclosure set forth above under Item 1.01 (Entry into a Material Definitive Agreement) is incorporated by reference into this Item 2.03. | enterologics_8k.htm |
| 2011-09-07 | 8-K | 2011-09-06 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 The disclosure set forth below under Item 2.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 1.01. 2.01 On September 6, 2011, Enterologics, Inc.(the “Company”), completed its acquisition of all of the shares of BioBalance Corp., a Delaware corporation (“BioBalance”), from New York Health Care, Inc., a New York corporation (the “Seller”), the sole owner of BioBalance, pursuant to a stock purchase agreement entered into on June 20, 2011 (the “Stock Purchase Agreement”) as previously reported and described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2011. 2.03 The disclosure set forth above under Item 2.01 is hereby incorporated by reference into this Item 2.03. 8.01 The disclosure set forth above under Item 2.01 is hereby incorporated by reference into this Item 8.01. | elgo_8k.htm |
| 2011-06-22 | 8-K | 2011-06-20 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On June 20, 2011, Enterologics, Inc., a Nevada corporation (“Enterologics”), and New York Health Care, Inc., a New York corporation (the “Seller”), entered into a stock purchase agreement (the “Purchase Agreement”) pursuant to which the Seller agreed to sell all of its shares of BioBalance Corp., a Delaware corporation and a wholly-owned subsidiary of the Seller (the “Company”), to Enterologics for a purchase price consisting of (i) $300,000 in cash, (ii) the assumption by Enterologics of up to $25,000 of liabilities of the Company and/or BioBalance LLC, a Delaware limited liability company (the “LLC”), as designated by the Company, (iii) either $100,000 in cash or the number of shares of common stock of Enterologics with an aggregate market value (calculated in accordance with the terms of the Purchase Agreement) of $150,000 (“Consideration Shares”), provided that the number of Consideration Shares shall not be less than 300,000 shares, as determined by Enterologics, and (iv) a three-year promissory note issued by Enterologics to the Seller in the original principal amount of $100,000 (the “Note”). 8.01 The disclosure set forth above under Item 1.01 (Entry Into a Material Definitive Agreement) is hereby incorporated by reference into this Item 8.01. | f8k062011_enterologics.htm |
| 2011-01-18 | 8-K | 2011-01-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On January 7, 2011, Enterologics, Inc., a Nevada corporation (the “Company”), entered into a letter agreement with Surge Partners, Ltd. (“Surge) for a loan commitment from Surge of up to $50,000. 2.03 The disclosure set forth above under Item 1.01 (Entry Into a Material Definitive Agreement) is hereby incorporated by reference into this Item 2.03. 3.02 The disclosure set forth above under Item 1.01 (Entry Into a Material Definitive Agreement) is hereby incorporated by reference into this Item 3.02. 8.01 The disclosure set forth above under Item 1.01 (Entry Into a Material Definitive Agreement) is hereby incorporated by reference into this Item 8.01. | f8k010711_enterologic.htm |
| 2011-01-13 | 8-K | 2011-01-12 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On January 12, 2011, Enterologics, Inc., a Nevada corporation (the “Company”), entered into a letter of intent (the “LOI”) with Universal Stabilization Technologies, Inc., a Delaware company (“UST”), setting forth the terms and conditions pursuant to which the Company will have the right of first refusal until May 15, 2012 (the “Option Period”) to enter into a definitive license agreement with UST (the “License Agreement”) pursuant to the license terms set forth in the LOI, for the exclusive worldwide license of UST’s intellectual property required exclusively for the preservation/stabilization of Escherichia coli (“E. coli”) probiotic bacteria and the protection of the Company’s use of E. coli bacteria as a probiotic (subject to the exceptions described in the LOI). 8.01 The disclosure set forth above under Item 1.01 (Entry Into a Material Definitive Agreement) is hereby incorporated by reference into this Item 8.01. | f8k011211_enterologics.htm |
| 2010-09-02 | 8-K | 2010-09-01 | 1.02 Termination of a Material Definitive Agreement | 1.02 On September 1, 2010 Enterologics, Inc., a Nevada corporation (“Enterologics”), informed New York Health Care, Inc., a New York corporation (“NYHC”) that it was terminating the binding letter of intent entered into between the parties on June 15, 2010 regarding the potential acquisition by Enterologics of all the intellectual property rights and property relating to biotherapeutic agents for the treatment of various gastrointestinal disorders from BioBalance LLC, a Delaware limited liability company. | f8k09110_enterologics.htm |
| 2010-06-16 | 8-K | 2010-06-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 15, 2010, Enterologics, Inc., a Nevada corporation (“Enterologics”), entered into a binding letter of intent (“LOI”) with New York Health Care, Inc., a New York corporation (“Seller”) and BioBalance LLC, a Delaware limited liability company (the “Company”), setting forth the terms pursuant to which Enterologics will acquire from Seller all of the Company’s intellectual property rights and property relating to biotherapeutic agents for the treatment of various gastrointestinal disorders (collectively, the “Assets”). | f8k061510_enterologics.htm |